293 related articles for article (PubMed ID: 31310010)
1. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
Hu B; Li H; Guo W; Sun YF; Zhang X; Tang WG; Yang LX; Xu Y; Tang XY; Ding GH; Qiu SJ; Zhou J; Li YX; Fan J; Yang XR
Int J Cancer; 2020 Mar; 146(6):1606-1617. PubMed ID: 31310010
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
3. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.
Wu Y; Wang J; Zheng X; Chen Y; Huang M; Huang Q; Xiao W; Wei H; Tian Z; Sun R; Sun C
Immunol Lett; 2020 Jul; 223():33-43. PubMed ID: 32335145
[TBL] [Abstract][Full Text] [Related]
5. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.
Gu Q; Zhang B; Sun H; Xu Q; Tan Y; Wang G; Luo Q; Xu W; Yang S; Li J; Fu J; Chen L; Yuan S; Liang G; Ji Q; Chen SH; Chan CC; Zhou W; Xu X; Wang H; Fang DD
Oncotarget; 2015 Aug; 6(24):20160-76. PubMed ID: 26062443
[TBL] [Abstract][Full Text] [Related]
6. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
7. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
Wu CX; Wang XQ; Chok SH; Man K; Tsang SHY; Chan ACY; Ma KW; Xia W; Cheung TT
Theranostics; 2018; 8(14):3737-3750. PubMed ID: 30083256
[No Abstract] [Full Text] [Related]
8. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
9. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Huang DQ; Muthiah MD; Zhou L; Jumat H; Tan WX; Lee GH; Lim SG; Kow A; Bonney G; Shridhar I; Lim YT; Wee A; Pang YH; Soon G; Chow P; Dan YY
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1313-1325. PubMed ID: 33340714
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer.
Xu W; Zhao ZY; An QM; Dong B; Lv A; Li CP; Guan XY; Tian XY; Wu JH; Hao CY
Int J Med Sci; 2020; 17(18):3073-3081. PubMed ID: 33173428
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
12. High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma.
Sun W; Li SC; Xu L; Zhong W; Wang ZG; Pan CZ; Li J; Jin GZ; Ta N; Dong W; Liu D; Liu H; Wang HY; Ding J
Clin Cancer Res; 2020 Aug; 26(16):4302-4312. PubMed ID: 32332018
[TBL] [Abstract][Full Text] [Related]
13. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
14. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
15. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
[No Abstract] [Full Text] [Related]
16. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
20. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]